Coherus BioSciences Inc. News
Regeneron's Eylea Win Leaves an Elephant in the Room
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
Biosimilars Are Saving America $1 Billion Per Month
Competitive drug prices are great for consumers. Turns out, they're good for industry, too.
Can This Small-Cap Biotech 5x Revenue by 2026?
It has one product on the market and up to four more launching by the end of 2023. The growth trajectory depends on execution.
FDA Approves Coherus' Version of Abbvie's Humira, Best-Selling Drug in the U.S.
Coherus was cleared by the FDA for a drug that's similar to AbbVie's Humira. Coherus plans to launch the psoriasis treatment in July 2023.
Five Below, Splunk, Snap: 'Mad Money' Lightning Round
Jim Cramer weighs in on Five Below, Splunk, Snap, Crown Castle, Square, 3D Systems, Dana, Alibaba, Coherus Biosciences.
The One-and-Wait Plan: Cramer's 'Mad Money' Recap
Jim Cramer's got a plan: Fed Chairman Jay Powell should hike once, then wait -- and maintain the independence of the Fed.
Five Rules For This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)
Even with Monday's sharp reversal, Jim Cramer says he still likes this market.
Biotech Movers: Acceleron, Clovis, Coherus
Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday.
Biotech Movers: Coherus, XBiotech, Flexion
Coherus BioSciences, XBiotech and Flexion Therapeutics were among the biotech stock movers in premarket trading on Monday.
AbbVie Stock Lower on Humira Patent Ruling
The drug is responsible for more than 60% of AbbVie's top line.
Breaking News
Tips for Retirees to Deal with Falling Stocks and Bonds
The markets' slide particularly hurts retirees, who may have to sell some of their stocks and bonds to finance spending.
Your Car Will Likely Be More Expensive
Ford has recently cast a shadow over the auto industry.
Short Sellers Targeted Commodities in September
Short sellers reversed course and sold $19 billion of shorts in September.
Alphabet CEO Pichai Continues to Sound Alarm About the Economy
The parent company of Google and Youtube is preparing for a sharp deterioration in the health of the economy.